Drug Induced Interstitial Lung Disease: Mechanism and Diagnostic Approach

Meghana Konkipudi

Konkipudi Meghana Priyadarshini Institute of Pharmaceutical Education and Research, 5th mile, Pulladigunta-522017, Guntur, Andhra Pradesh. India.

Abstract

To achieve remission or stabilize the course of the disease, clinicians may encounter substantial challenges in creating a patient-centered, tailored therapeutic plan and generating a reliable analysis of a particular type of interstitial lung disease (ILD). A precise diagnosis of the specific form of ILD must be made when a patient is evaluated for suspected ILD. Only then can an appropriate organization plan be developed, with the goal of relieving symptoms and restoring or significantly improving quality of life while also providing the patient with useful prognostic information. In order to arrive at a multidisciplinary consensus diagnosis, the results of lung biopsies and lavage are examined. The gold standard for diagnosing interstitial lung disease is a multidisciplinary approach that includes significant aspects of the patient's medical history and physical examination, a blood panel, pulmonary function tests, high resolution computed tomography imaging, and, if necessary, bronchoalveolar lavage. Future management of interstitial lung disease will be influenced by advancements such as the introduction of the disease-modifying anti-fibrotic medicines pirfenidone and nonreading.

Keywords: ILD, Infection, fibrotic pattern, respiratory tract

References

1. Allen JN, Davis WB, Pacht ER. Diagnostic significance of increased bronchoalveolar lavage fluid eosinophils. American Review of Respiratory Disease. 1990 Sep;142(3):642-7.
2. Blum RH, Carter SK, Agre K. A clinical review of bleomycin—a new antineoplastic agent. Cancer. 1973 Apr;31(4):903-14.
https://pubmed.ncbi.nlm.nih.gov/4122362/
3. Amulya A, Sirisha V, Rao CB, Chennam JV. CURRENT TRENDS ON ROLE OF NANO PARTICLES ON PULMONARY DISEASES. International Journal of Research in Pharmacy and Chemistry. 2012;2(3):685-703.
4. Cooper Jr JA, White DA, Matthay RA. Drug-induced pulmonary disease: Part 1: Cytotoxic drugs. American Review of Respiratory Disease. 1986 Feb;133(2):321-40. https://pubmed.ncbi.nlm.nih.gov/2869727/
5. Gindi S, Hawisa NT, Baburao C, Khagga M. Role of Ficus bengalensis leaves as a hepatoprotective on rifampicin induced hepatic damage in albino rats. Research Journal of Pharmacology and Pharmacodynamics. 2010;2(6):378-9.
6. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004 Aug 13;71(4):301-26.
https://pubmed.ncbi.nlm.nih.gov/15316202/
7. Dey B, Hwisa NT, Khalf AM, Mitra A, Katakam P, Rao CB. Pharmaco-epidemiological Studies on Self Medication and Drug Utilization Pattern in Chronic Diseases via Prescription Auditing. International Journal of Scientific Research in Knowledge. 2013 Nov 1;1(11):464. (PDF) Pharmaco-epidemiological Studies on Self Medication and Drug Utilization Pattern in Chronic Diseases via Prescription Auditing (researchgate.net)
8. Li S, Shi J, Tang H. Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics. Cell Biology And Toxicology. 2022 Oct;38(5):699-723.
9. Kupferschmid JP, Rosengart TK, McIntosh CL, Leon MB, Clark RE. Amiodarone-induced complications after cardiac operation for obstructive hypertrophic cardiomyopathy. The Annals of thoracic surgery. 1989 Sep 1;48(3):359-64.
https://pubmed.ncbi.nlm.nih.gov/2774719/
10. Kumar KR, Nagaraju GV, Subrahmanyam SN, Nagarani K, Shareef S, Tennygilphin M, Namballa M. Assessment on Elements Involving the Academic Performance among Pharmacy Students: A Cross-Sectional Observational Study. Int J Cur Res Rev| Vol. 2021 Dec;13(23):141.
11. Limper AH. Chemotherapy-induced lung disease. Clinics in chest medicine. 2004 Mar 1;25(1):53-64.
12. Logan PM, Primack SL, Staples C, Miller RR, Müller NL. Acute lung disease in the immunocompromised host: diagnostic accuracy of the chest radiograph. Chest. 1995 Nov 1;108(5):1283-7. https://pubmed.ncbi.nlm.nih.gov/7587430/
13. Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. European Journal of Cancer. 2006 Aug 1;42(12):1875-80.
14. Meyer KC. Interstitial lung disease in the elderly: pathogenesis, diagnosis and management. Sarcoidosis Vasc Diffuse Lung Dis. 2011 Jul 1;28(1):3-17. https://pubmed.ncbi.nlm.nih.gov/21796886/
15. McFadden RG, Fraher LJ, Thompson JM. Gold-naproxen pneumonitis: a toxic drug interaction?. Chest. 1989 Jul 1;96(1):216-8.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426467
16. O’sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Annals of Oncology. 2003 Jan 1;14(1):91-6. https://www.sciencedirect.com/science/article/pii/S0923753419639116
17. Pietra GG. Pathologic mechanisms of drug-induced lung disorders. Journal of thoracic imaging. 1991 Jan 1;6(1):1-7.
18. Ravella S, Angel M, Subramanian H, Thangavel N, Namballa M, Lokesh D, Mishra AK, Nagaraju GV. Navigating the Future of Cancer Diagnosis: A Comprehensive Review of Novel Approaches for Community-Based Treatment. future.;1:6.
19. Penn RG, Griffin JP. Adverse reactions to nitrofurantoin in the United Kingdom, Sweden, and Holland. Br Med J (Clin Res Ed). 1982 May 15;284(6327):1440-2.
20. Potente G, Bellelli A, Nardis P. Specific diagnosis by CT and HRCT in six chronic lung diseases. Computerized medical imaging and graphics. 1992 Jul 1;16(4):277-82.